Comparative Pharmacology
Head-to-head clinical analysis: NALOXONE versus OPVEE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALOXONE versus OPVEE.
NALOXONE vs OPVEE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid effects.
Opvee is a naloxone-containing nasal spray. Naloxone is an opioid antagonist that competitively binds to mu-opioid receptors, reversing opioid-induced respiratory depression and sedation.
0.4-2 mg IV/IM/SC, may repeat every 2-3 minutes; if no response after 10 mg, reconsider diagnosis.
2 mg intranasally as a single dose; may repeat every 2-3 minutes if response is inadequate; maximum total dose of 4 mg.
None Documented
None Documented
60-90 minutes in adults; shorter in neonates (3 hours); prolonged in hepatic impairment (up to 2-3 hours).
Clinical Note
moderateNaloxone + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Naloxone."
Clinical Note
moderateNaloxone + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Naloxone."
Clinical Note
moderateNaloxone + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Naloxone."
Clinical Note
moderateNaloxone + Cyclosporine
Terminal elimination half-life is approximately 2-4 hours (mean 2.8 hours) in healthy adults. Context: Despite short half-life, clinical antagonism of opioids can persist for 1-2 hours, potentially shorter than the opioid; repeat dosing may be needed.
Renal: ~70% as metabolites (naloxone-3-glucuronide, naloxone-3-sulfate) and <2% unchanged; biliary/fecal: ~25% primarily as conjugated metabolites.
Primarily renal excretion of unchanged drug (approximately 50-70%) and conjugated metabolites (glucuronide); the remainder is eliminated via biliary/fecal routes. Total renal clearance accounts for ~60% of systemic clearance.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist
"The metabolism of Cyclosporine can be decreased when combined with Naloxone."